BENEFITS AND RISKS OF USING ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN NON-SMALL CELL LUNG CANCER (NSCLC) AND SMALL CELL LUNG CANCER (SCLC) PATIENTS: RESULTS FROM STUDY-LEVEL AND PATIENT-LEVEL META-ANALYSES OF CONTROLLED ESA TRIALS IN LUNG CANCER

被引：0

作者：

Vansteenkiste, Johan ^{[1
]}

Glaspy, John ^{[2
]}

Henry, David ^{[3
]}

Ludwig, Heinz ^{[4
]}

Pirker, Robert ^{[5
]}

Tomita, Dianne ^{[6
]}

Collins, Helen ^{[6
]}

Crawford, Jeffrey ^{[7
]}

机构：

[1] Univ Hosp Gasthuisberg, Resp Oncol Unit, Louvain, Belgium

[2] Univ Calif Los Angeles, Los Angeles, CA 90024 USA

[3] Univ Penn, Philadelphia, PA 19104 USA

[4] Wilhelminenspital Stadt Wien, Vienna, Austria

[5] Med Univ Vienna, Dept Med 1, Vienna, Austria

[6] Amgen Inc, Thousand Oaks, CA 91320 USA

[7] Duke Univ, Med Ctr, Durham, NC 27706 USA

来源：

关键词：

meta-analysis; SCLC; NSCLC; mortality;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S645 / S646

页数：2